Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gabriel Chodick, Sarah Sharman Moser & Inbal Goldshtein. (2016) Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 359-370.
Read now
Read now
Jörg Schilcher. (2013) Epidemiology, radiology and histology of atypical femoral fractures. Acta Orthopaedica 84:sup352, pages 1-26.
Read now
Read now
R. Akehurst, N. Brereton, R. Ariely, T. Lusa, M. Groot, P. Foss & S. Boonen. (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. Journal of Medical Economics 14:1, pages 53-64.
Read now
Read now
Articles from other publishers (14)
O. Ström, R. Lauppe, Ö. Ljunggren, A. Spångéus, G. Ortsäter, J. O’Kelly & K. Åkesson. (2020) Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporosis International 31:8, pages 1525-1533.
Crossref
Crossref
Stuart L. Silverman & Deborah T. Gold. 2018. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
593
596
.
Linda Karlsson, Johan Mesterton, Maurille Feudjo Tepie, Michele Intorcia, Jetty Overbeek & Oskar Ström. (2017) Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control. Archives of Osteoporosis 12:1.
Crossref
Crossref
Rebecca L. Drieling, Andrea Z. LaCroix, Shirley A. A. Beresford, Denise M. Boudreau, Charles Kooperberg, Rowan T. Chlebowski, Marcia G. Ko & Susan R. Heckbert. (2017) Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. Journal of the American Geriatrics Society 65:9, pages 1924-1931.
Crossref
Crossref
Susan M. Ott. (2016) Long-term bisphosphonates: primum non nocere. Menopause 23:11, pages 1159-1161.
Crossref
Crossref
Rebecca L. Drieling, Andrea Z. LaCroix, Shirley A.A. Beresford, Denise M. Boudreau, Charles Kooperberg, Rowan T. Chlebowski, Margery Gass, Carolyn J. Crandall, Catherine R. WomackSusan R. Heckbert. (2016) Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause 23:11, pages 1168-1175.
Crossref
Crossref
C. Klop, P. M. J. Welsing, P. J. M. Elders, J. A. Overbeek, P. C. Souverein, A. M. Burden, H. A. W. van Onzenoort, H. G. M. Leufkens, J. W. J. Bijlsma & F. de Vries. (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporosis International 26:6, pages 1831-1840.
Crossref
Crossref
M. M. Bonafede, N. Shi, A. G. Bower, R. L. Barron, A. Grauer & D. B. Chandler. (2015) Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporosis International 26:3, pages 1203-1212.
Crossref
Crossref
Shonda A Foster, Nianwen Shi, Suellen Curkendall, John Stock, Bong-Chul Chu, Russel Burge, David R Diakun & John H Krege. (2013) Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Women's Health 13:1.
Crossref
Crossref
T. Thomas, S. Horlait, J. D. Ringe, A. Abelson, D. T. Gold, P. Atlan & J. L. Lange. (2012) Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporosis International 24:1, pages 263-269.
Crossref
Crossref
Richard M Dell, Annette L Adams, Denise F Greene, Tadashi T Funahashi, Stuart L Silverman, Eric O Eisemon, Hui Zhou, Raoul J Burchette & Susan M Ott. (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. Journal of Bone and Mineral Research 27:12, pages 2544-2550.
Crossref
Crossref
Serge Ferrari, Toshitaka Nakamura, Hiroshi Hagino, Saeko Fujiwara, Jeffrey L. Lange & Nelson B. Watts. (2011) Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. Journal of Bone and Mineral Metabolism 29:5, pages 561-570.
Crossref
Crossref
Milica Nikitovic, Daniel H. Solomon & Suzanne M. Cadarette. (2010) Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Therapeutic Advances in Chronic Disease 1:4, pages 149-162.
Crossref
Crossref
A. Abelson, J. D. Ringe, D. T. Gold, J. L. Lange & T. Thomas. (2009) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporosis International 21:6, pages 1021-1029.
Crossref
Crossref